Bessemer Group Inc. Purchases 6,225 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Bessemer Group Inc. raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 1.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 582,269 shares of the company's stock after buying an additional 6,225 shares during the period. Bessemer Group Inc. owned 1.93% of Medpace worth $177,411,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new position in shares of Medpace in the fourth quarter valued at approximately $31,000. Jones Financial Companies Lllp increased its holdings in Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after purchasing an additional 110 shares in the last quarter. Lindbrook Capital LLC raised its position in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the last quarter. Assetmark Inc. boosted its stake in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after purchasing an additional 29 shares in the last quarter. Finally, Colonial Trust Co SC boosted its stake in Medpace by 150.0% in the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after purchasing an additional 105 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $315.28 on Wednesday. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $459.77. The firm has a market capitalization of $9.06 billion, a P/E ratio of 24.07, a P/E/G ratio of 5.57 and a beta of 1.47. The company's 50 day simple moving average is $300.15 and its 200 day simple moving average is $320.83.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $3.06 by $0.61. The company had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. Medpace had a net margin of 19.31% and a return on equity of 54.36%. During the same quarter in the previous year, the company posted $3.20 EPS. Sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on MEDP shares. Robert W. Baird lowered their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Leerink Partners initiated coverage on shares of Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective for the company. Truist Financial dropped their target price on shares of Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research note on Wednesday, April 23rd. Barclays began coverage on shares of Medpace in a research report on Tuesday. They set an "equal weight" rating and a $300.00 target price on the stock. Finally, TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and lowered their price target for the company from $370.00 to $328.00 in a report on Monday, April 14th. Twelve investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $344.82.

Insider Activity at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the transaction, the director now owns 2,998 shares of the company's stock, valued at $904,856.36. This trade represents a 36.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 20.30% of the stock is currently owned by corporate insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.